Car-t plus herceptin for her2-positive advanced cancer
Part of Cancer clinical trials.
This trial tests a new type of cell therapy (CAR-T cells) combined with a drug called trastuzumab (Herceptin) for HER2-positive advanced cancers, especially breast cancer. It aims to see if this combination can shrink or slow the tumor when other treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 21 years old.
- Your cancer is HER2-positive (a specific protein found on some cancer cells).
- You have already tried at least two types of anti-HER2 therapy (like Herceptin) and they stopped working.
- You have measurable disease (doctors can see the tumor on scans).
- You are fit enough to be up and about (ECOG 0-1).
- Your heart function is at least 50% and your major organs (liver, kidneys, bone marrow) are working well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immunotherapy called CAR-T cells that are designed to attack cancer cells that have a high amount of a protein called HER2. It is for people with advanced solid tumors (like certain breast, stomach, or lung cancers) that have not responded to standard treatments.
This trial tests a new type of immune cell therapy (CAR T cells) that targets two markers on cancer cells: TRAIL-R2 and HER2. It is for people with advanced or recurrent HER2-positive breast cancer that has not been stopped by standard treatment.
This study tests a new type of cell therapy called anti-HER2-CAR-T for people with advanced HER2-positive solid tumors (like breast, stomach, or colon cancer) whose cancer has not responded to other treatments. The therapy uses your own immune cells engineered to target and kill cancer cells.
This trial tests an experimental 'off-the-shelf' CAR-T cell therapy (called FT825/ONO-8250) that targets a protein called HER2 found on some solid tumors. It may be given alone or with other antibodies to help fight advanced cancer that has not responded to standard treatments.
This trial tests a new immune-cell therapy (CAR-T) that targets a protein called HER2 in people with advanced or metastatic solid cancers. It may help shrink tumors and control the disease after standard treatments have failed or when there is no clear standard option.
This early-stage trial tests a new type of immune cell therapy called CAR-T cells, which are designed to recognize and attack cancer cells that have a protein called HER2. The cells are made from your own immune cells, trained in the laboratory, and given back to you. The study evaluates how safe the treatment is and whether it can shrink tumors.
Hear when a new Other Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.